Nuvectis Pharma FY2024 EPS Estimate Boosted by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Stock analysts at Roth Capital increased their FY2024 EPS estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will earn ($1.00) per share for the year, up from their previous forecast of ($1.02). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at $1.64 EPS.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same period last year, the company posted ($0.37) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Nuvectis Pharma Trading Up 9.7 %

Shares of NVCT opened at $8.15 on Thursday. The stock has a market capitalization of $152.00 million, a price-to-earnings ratio of -6.32 and a beta of 0.41. Nuvectis Pharma has a 12 month low of $5.85 and a 12 month high of $12.10. The firm has a fifty day simple moving average of $6.81 and a 200 day simple moving average of $6.68.

Institutional Investors Weigh In On Nuvectis Pharma

Large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Nuvectis Pharma during the second quarter worth $58,000. Nations Financial Group Inc. IA ADV acquired a new stake in Nuvectis Pharma in the 3rd quarter valued at about $63,000. Baxter Bros Inc. bought a new position in Nuvectis Pharma during the second quarter worth about $79,000. GSA Capital Partners LLP increased its position in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after buying an additional 1,790 shares during the last quarter. Finally, Iridian Asset Management LLC CT bought a new stake in Nuvectis Pharma in the third quarter valued at approximately $348,000. Institutional investors and hedge funds own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.